296 related articles for article (PubMed ID: 29068496)
1. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
4. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
5. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
7. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
9. Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability.
Masud T; Giannini S
Aging Clin Exp Res; 2003 Apr; 15(2):89-98. PubMed ID: 12889839
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
12. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
13. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
[TBL] [Abstract][Full Text] [Related]
15. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.
Miller PD
Curr Med Res Opin; 2008 Jan; 24(1):107-19. PubMed ID: 18031594
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate treatment of osteoporosis.
Watts NB
Clin Geriatr Med; 2003 May; 19(2):395-414. PubMed ID: 12916293
[TBL] [Abstract][Full Text] [Related]
17. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
[TBL] [Abstract][Full Text] [Related]
18. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
Boling EP
Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
[TBL] [Abstract][Full Text] [Related]
19. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
20. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]